Literature DB >> 33859787

Novel Pyridazinones as TRPC5 Inhibitors for Treating Kidney Diseases.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 33859787      PMCID： PMC8040034          DOI： 10.1021/acsmedchemlett.1c00123

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  Review of Transient Receptor Potential Canonical (TRPC5) Channel Modulators and Diseases.

Authors:  Swagat Sharma; Corey R Hopkins
Journal:  J Med Chem       Date:  2019-04-17       Impact factor: 7.446

Review 2.  Transient receptor potential channel regulation by growth factors.

Authors:  Charlotte Van den Eynde; Joris Vriens; Katrien De Clercq
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-01-07       Impact factor: 4.739

Review 3.  Charting a TRP to Novel Therapeutic Destinations for Kidney Diseases.

Authors:  Juan Lorenzo Pablo; Anna Greka
Journal:  Trends Pharmacol Sci       Date:  2019-11-05       Impact factor: 14.819

Review 4.  TRPC channels: Regulation, dysregulation and contributions to chronic kidney disease.

Authors:  Stuart E Dryer; Hila Roshanravan; Eun Young Kim
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-04-04       Impact factor: 5.187

Review 5.  Genetic susceptibility of hypertension-induced kidney disease.

Authors:  Chao Zhang; Xing Fang; Huawei Zhang; Wenjun Gao; Han Jen Hsu; Richard J Roman; Fan Fan
Journal:  Physiol Rep       Date:  2021-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.